UNION therapeutics' COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication

HELLERUP, Denmark, April 6, 2021 /PRNewswire/ — UNION therapeutics A/S (UNION) announced today that the results of a phase 1 study of inhaled and intranasal niclosamide (UNI911) have been published by The Lancet Regional Health – Europe (LINK). With no serious adverse effects reported,…


Continue Reading

HEDGE accordingly